CytomX Therapeutics Inc [NASDAQ: CTMX] slipped around -0.07 points on Tuesday, while shares priced at $2.06 at the close of the session, down -3.29%.
Compared to the average trading volume of 4.98M shares, CTMX reached a trading volume of 7573061 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CytomX Therapeutics Inc [CTMX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTMX shares is $4.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTMX stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for CytomX Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 15, 2025. While these analysts kept the previous recommendation, Piper Sandler dropped their target price from $3.25 to $2.50. The new note on the price target was released on April 14, 2025, representing the official price target for CytomX Therapeutics Inc stock. Previously, the target price had yet another raise from $2.25 to $3.50, while Piper Sandler kept a Overweight rating on CTMX stock.
The Average True Range (ATR) for CytomX Therapeutics Inc is set at 0.26, with the Price to Sales ratio for CTMX stock in the period of the last 12 months amounting to 2.20. The Price to Book ratio for the last quarter was 6.63, with the Price to Cash per share for the same quarter was set at 0.51.
How has CTMX stock performed recently?
CytomX Therapeutics Inc [CTMX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.60. With this latest performance, CTMX shares gained by 174.70% in over the last four-week period, additionally plugging by 106.00% over the last 6 months – not to mention a rise of 3.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTMX stock in for the last two-week period is set at 69.00, with the RSI for the last a single of trading hit 67.49, and the three-weeks RSI is set at 68.94 for CytomX Therapeutics Inc [CTMX]. The present Moving Average for the last 50 days of trading for this stock 0.88, while it was recorded at 2.12 for the last single week of trading, and 1.00 for the last 200 days.
CytomX Therapeutics Inc [CTMX]: Deeper insight into the fundamentals
CytomX Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.73 and a Current Ratio set at 1.73.
Insider trade positions for CytomX Therapeutics Inc [CTMX]
There are presently around $35.45%, or 35.66%% of CTMX stock, in the hands of institutional investors. The top three institutional holders of CTMX stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 7.79 million shares, which is approximately 9.1799%. JANUS HENDERSON GROUP PLC, holding 6.3 million shares of the stock with an approximate value of $$7.72 million in CTMX stocks shares; and JANUS HENDERSON GROUP PLC, currently with $$6.38 million in CTMX stock with ownership which is approximately 6.1598%.
